Fourth Quarter and Year End 2012 Financial Results Conference Call
February 28, 2013
Fourth Quarter and Year End 2012 Financial Results Conference Call - - PowerPoint PPT Presentation
Fourth Quarter and Year End 2012 Financial Results Conference Call February 28, 2013 Forward-looking Statements Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements, including, but
February 28, 2013
1
Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements, including, but not limited to, statements regarding expected gain of future market share, product sales growth, synergies, cash flow initiatives and
“anticipates,” “expects,” “intends,” “plans,” “could,” “should,” “would,” “may,” “will,” “believes,” “estimates,” “potential,”
those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes. Non-GAAP Information To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the company uses non-GAAP financial measures that exclude certain items, such as amortization of inventory step-up, amortization of alliance product assets & pp&e step up, stock-based compensation step-up, contingent consideration fair value adjustments, restructuring, acquisition-related and other costs, acquired in-process research and development ("IPR&D"), legal settlements outside the ordinary course of business, the impact of currency fluctuations, amortization and
loss on extinguishment of debt, (gain) loss on assets held for sale/impairment, net, (gain) loss on investments, net, and adjusts tax expense to cash taxes. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a meaningful, consistent comparison of the company’s core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP. Therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.
2
3
Q4 2012 % 2012 % Product Sales $947 M 45% $3,310 M 47% Total Revenue $986 M 43% $3,547 M 44% Cash EPS $1.22 30% $4.51 54% Cash EPS Excluding Medicis interest expense $1.34 43% $4.63 58% Adjusted Cash Flow from Operations $423 M 67% $1,294 M 40%
4
Same Store Sales* Q4 2012 FY 2012 U.S. Derm/Promoted 17% 32% U.S. Neuro 3%
Canada / Australia 1
Emerging Markets 12% 11% Total 7% 8% Pro Forma* Q4 2012 FY 2012 U.S. Derm/Promoted 15% 25% U.S. Neuro 3%
Canada / Australia 2
1% Emerging Markets 15% 13% Total 9% 10%
* Adjusts for the impact of foreign exchange, acquisitions, divestitures/discontinuations, and includes JV revenues
1 Excluding Cesamet, the Canadian / Australian segment delivered Q4 5% organic growth (same store) and 6% (pro forma) 2 Excluding Cesamet, the Canadian / Australian segment delivered 2012 12% organic growth (same store) and 9% (pro forma)
5
$322 $308 $241 $423
1st Qtr* 2nd Qtr* 3rd Qtr 4th Qtr
* Includes $66M Q1 dermatology divestitures and $45M Q2 milestone payment from GSK Excluded Items:
Related Costs
6
Revenue $3.1-$3.4 billion Cash EPS $3.95 - $4.20 >$1.2 billion in Adjusted
Cash Flow from Operations
Revenue $3.5 billion Cash EPS $4.51 $1.3 billion in Adjusted
Cash Flow from Operations
Organic Growth: 8% same store sales 10% pro forma
7
Poland
Market shrank 6% while Valeant grew 3% Fastest growing pharmaceutical company in Poland; 1 of only 2 pharmaceutical
companies that delivered positive organic growth in 2012
Continue to gain market share as the overall Polish market returns to growth in 2013
South East Asia/South Africa
Delivered growth of 20% in constant currency Both operations realize operating margins above 40%
U.S. Neurology & Other
After 6 quarters of decreases, delivered positive growth in Q412 Wellbutrin XL scripts have now leveled off; expect growth in products sales in 2013
U.S. Dermatology
Double digit growth in key Rx dermatology brands - Elidel, Zovirax, Xerese, Acanya,
Retin–A Micro
Other non-dermatology Rx business units also grew double digit - OraPharma,
Mexico
Delivered greater than 10% organic growth (pro forma) Successfully added Atlantis acquisition to the portfolio
8
Business Development
Natur Produkt closed February 1 Acquired OTC assets from Lek-am in Poland February 12 Acquired Targretin from Eisai February 21
Medicis Integration Update
Integration on track – pursuing legal / R&D synergies Sales force now fully trained and back in the field Continue to see more upsides than downsides to original deal model
R&D / Product Updates
Luliconazole PDUFA date set for December 11, 2013 Dysport launched in Canada Efinaconazole on track for May 23 PDUFA date 2 Emervel fillers to be filed in 2013 MetroGel 1.3% Hydrogel (Bacterial Vaginosis) to be filed 1H 2013
We will wait until Q1 2013 conference call to update financial
guidance
10
Q4 2011 Q4 2012 FY 2011 FY 2012 Product Sales $654M $947M $2,255M $3,310M Ongoing Service/Alliance Revenue $34M $39M $132 M $126M Total Revenue excl. “one-timers” $688M $986M $2,387M $3,436M One-time items N/A N/A $76M $111M Total Revenue $688M $986M $2,463M $3,547M Cost of Goods Sold% 2 (% of product
sales)
25% 25% 27% 24% SG&A% 2 (% of total revenue) 20% 20% 21% 20% R&D Expense $17M $20M $65M $79M EBITA Margin 1 (% of total revenue) 54% 53% 51% 53% Cash EPS (Reported) $0.94 $1.22 $2.93 $4.51 w/o one-time items $0.87 $1.22 $2.64 $4.14 Adjusted Cash Flow from Operations $253M $423M $925M $1,294M Fully Diluted Share Count 317 M 312M 326 M 313M
1 Excludes all non-operating expenses 2 Excludes adjustments per Press Tables 2a & 2b
11
Q1 11 Q2 11 Q3 11 Q4 11 Q1 12 Q2 12 Q3 12 Q4 12 Reported Revenues ($M) $565 $609 $601 $688 $856 $820 $884 $986 Sale Cloderm/5FU/IDP111
Milestones
Revenue excl. one-time items ($M) $529 $569 $601 $688 $790 $775 $884 $986 Revenue Growth (vs PY) 17% 15% 28% 34% 49% 36% 47% 43% Reported Cash EPS $0.62 $0.73 $0.66 $0.94 $1.14 $1.01 $1.15 $1.22 Sale Cloderm/5FU/IDP111 (margin)
Milestones
Gain on Cephalon Shares
One-time Fx Gains
Cash EPS excl. one-time items $0.56 $0.54 $0.66 $0.87 $0.91 $0.87 $1.15 $1.22 Cash EPS Growth (vs Prior Year)* 28% 17% 65% 75% 61% 61% 75% 40% Base Business Cash Earnings ($M) $188 $179 $212 $277 $287 $269 $357 $380 Cash Earnings / Revenue 36% 31% 35% 40% 36% 35% 40% 39% Cash Earnings / Revenue (LTM) 32% 32% 34% 36% 36% 37% 38% 38%
* Cash EPS excluding one-time items was $1.34 (54% growth vs Q4 ’11) excluding Medicis related financing.
12
($ in millions)
1 Accelerated vesting of Medicis stock based compensation of $76M expensed and paid upon closing and payment of
Medicis stock appreciation rights and other compensation of $58M that was accrued by Medicis prior to close and paid post-close
Restructuring Related Costs Amount Paid
Severance Payments $78.0 Acquisition Related Costs Paid to 3rd Parties $23.7 Integration Related Consulting, Duplicative Labor, Transition Services, and Other $3.5 Costs Incurred to date to Achieve Synergies $105.2
Pre-acquisition Related Costs Amount Paid
Stock Based Compensation 1 $134.7 Medicis Advisory & Legal Fees $47.0 Total $181.7
13
$2,463 $327 $1,023 $35 $161 $39 $101 $3,547
2011 Rev Base Growth Acquisitions One-Tim ers* Generics Divestitures Foreign Exchange 2012 Rev
* One-time items Include incremental revenue received from one-time items of $111M received in 2012 over $76M received in 2011
14
We have set working capital targets for each
We are diligently tracking all restructuring costs
More disciplined approach for the deal model and restructuring
efforts
We are performing monthly working capital reviews
Cash Flow objectives have been built into the GM’s
February 28, 2013